Elvina Almuradova, Associate Professor of Oncology at the European Institute of Oncology (IEO), shared a post on X:
” 1L: AI or Fulv + CDK4/6i
2L:
PI3K and ESR1 wt: Fulv + Everolimus / Abemaciclib
ESR1 mut: Elacestrant
PI3K mut: Fulv + Alpelisib / Capivasertib
3L+: Options incl. chemo, Elacestrant, Olaparib, T-DXd
4L+: SG, DATO-DXd, biomarkers”
More posts featuring Elvina Almuradova